Clinical Study
Epidemiological Clinical Features and Evolution of Gastroduodenal Ulcer Bleeding in a Tertiary Care Hospital in Spain, during the Last Seven Years
Table 1
Demographic and clinical characteristics of patients with peptic ulcer bleeding.
| | | 2006
() | 2007
() | 2008
() | 2009
() | 2010
() | 2011
() | 2012
() | P |
| | Male gender, n (%) | 25 (67.6) | 32 (82.1) | 36 (76.6) | 28 (60.9) | 26 (70.3) | 19 (65.5) | 27 (73) | 0.4 | Age (mean ± SD, years)
Range |
(20–93) |
(19–93) |
(21–91) |
(25–91) |
(28–88) |
(27–93) |
(28–99) | 0.7 | | Comorbidities, n (%) | 19 (51.4) | 19 (48.7) | 21 (44.7) | 22 (47.8) | 14 (37.8) | 17 (58.6) | 19 (51.4) | 0.8 | | Drugsa, n (%) | 20 (54.1) | 20 (51.3) | 27 (57.4) | 27 (58.7) | 23 (62.2) | 14 (48.3) | 25 (67.6) | 0.7 | | Prior peptic ulcer, n (%) | 5 (13.5) | 3 (7.7) | 9 (19.1) | 6 (13.0) | 11 (29.7) | 5 (17.2) | 6 (16.2) | 0.3 |
|
|
Aspirin (AAS), non-steroidal anti-inflammatory drugs (NSAID), antiplatelet therapy, and/or anticoagulant drugs.
|
